About Us
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries.
Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups and other stakeholders, to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with ten patent holders for thirteen HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals and a tuberculosis treatment. MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC).
Featured
Discover MedsPaL
MedsPaL, MPP’s medicines patents and licences database, is a free resource that provides information on the intellectual property status of selected patented essential medicines in low- and middle-income countries.
MPP in Numbers
patent holders with MPP signed agreements
generic manufacturers and product developers have sublicences from MPP
countries have benefitted from access to MPP-licensed products
ongoing pharmaceutical development projects
Billion dollars saved by the international community, from January 2012 to December 2020
Billion doses of treatment supplied from January 2012 to December 2020
Million patient-years of treatment through MPP’s generic partners, from January 2012 to December 2020
For Everyone Everywhere
Discover where we helped and what we have achieved
Patent and licensing status: last updated on 11 May 2021. Disclaimer | Product availability data from MPP sublicensees: last updated in June 2021 (data as of 31 March 2021) | Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions
Impact Stories
How access to antiretrovirals is building the future
Key Publications
Prioritising Medicines for Licensing
02 March 2020
Twitter Feed
MedicinesPatentPool @MedsPatentPool
👏MPP congratulates @fiocruz_en 🇧🇷 and @Sinergiumbio 🇦🇷 for their selection by @WHO to work on the dvpt and production of #mRNA #vaccines in the #Americas and to collaborate with the mRNA #TechTransfer hub based in #SouthAfrica🇿🇦. #PublicHealth #HealthForAll #COVID19 @pahowho https://t.co/oCoLB6MfYq
MedicinesPatentPool @MedsPatentPool
👏@UNITAID, who funds both @MedsPatentPool and the @LivUni #LONGEVITY project, has been an instrumental partner in contributing to speeding up the development of long-acting medicine formulations for #LMICs. 👉https://t.co/ib8m0fjF9f @CELTLiverpool @tandemnano https://t.co/NM0n6WnCTN
Centre of Excellence for Long-acting Therapeutics @CELTLiverpool
We are delighted that @MedsPatentPool & @tandemnano have reached this crucial milestone. This is a huge step forward in ensuring our life-saving #longacting formulations can be accessed by patients in need living in low- and middle-income countries. #malaria #tuberculosis #hepc https://t.co/ELgB07w0cY
